Spil Company Profile
What is the competitive landscape for SPIL
SPIL has six approved drugs.
There are five US patents protecting SPIL drugs.
Summary for Spil
| US Patents: | 5 |
| Tradenames: | 6 |
| Ingredients: | 6 |
| NDAs: | 6 |
Drugs and US Patents for Spil
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Spil | NIFEDIPINE | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 210838-003 | Apr 16, 2019 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Spil | POMALIDOMIDE | pomalidomide | CAPSULE;ORAL | 210232-002 | Aug 31, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Spil | POMALIDOMIDE | pomalidomide | CAPSULE;ORAL | 210232-003 | Aug 31, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Spil | POMALIDOMIDE | pomalidomide | CAPSULE;ORAL | 210232-001 | Aug 31, 2026 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Spil | KAPSPARGO SPRINKLE | metoprolol succinate | CAPSULE, EXTENDED RELEASE;ORAL | 210428-004 | Jan 26, 2018 | RX | Yes | Yes | 9,504,655 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Spil | OMEPRAZOLE MAGNESIUM | omeprazole magnesium | CAPSULE, DELAYED RELEASE;ORAL | 210593-001 | Jul 20, 2018 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Spil Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 2016005934 | ⤷ Start Trial |
| European Patent Office | 4578510 | ⤷ Start Trial |
| European Patent Office | 3409273 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2016005934 | ⤷ Start Trial |
| Japan | 6626492 | ⤷ Start Trial |
| Japan | 2017523164 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Spil Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0984957 | 2012/048 | Ireland | ⤷ Start Trial | PRODUCT NAME: A COMBINATION PRODUCT COMPRISING ASPIRIN AND ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; NAT REGISTRATION NO/DATE: PA 970/063/001 20120831; FIRST REGISTRATION NO/DATE: 5402359; 5402367 5402375 20110812 |
| 2105135 | 300717 | Netherlands | ⤷ Start Trial | PRODUCT NAME: POMALIDOMIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN, SOLVATEN, HYDRATEN OF STEREOISOMEREN DAARVAN; REGISTRATION NO/DATE: EU/1/13/850 20130805 |
| 1109558 | 2008/034 | Ireland | ⤷ Start Trial | PRODUCT NAME: RANOLAZINE OR A SALT THEREOF; REGISTRATION NO/DATE: EU/1/08/462/001 20080709 |
| 0984957 | SPC/GB11/013 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE; REGISTERED: UK PL 17901/0263-0001 20101105 |
| 2105135 | 1590004-6 | Sweden | ⤷ Start Trial | PRODUCT NAME: POMALIDOMIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS, SOLVATES, HYDRATES OR STEREOISOMERS THEREOF; REG. NO/DATE: EU/1/13/850 20130808 |
| 1411900 | 2011C/016 | Belgium | ⤷ Start Trial | PRODUCT NAME: NAPROXENE ET ESOMEPRAZOLE (SOUS LA FORME D'ESOMEPRAZOLE MAGNESIUM TRIHYDRATE); AUTHORISATION NUMBER AND DATE: BE382505 20101214 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
